Additional file 1: of Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

Table listing the Central ethics committee and the IRBs of the participating institutes. The IRB of each participating institute reviewed and approved the protocol of the present study. (DOCX 17 kb)